Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BRONKOSOL vs AEROLATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular c AMP, leading to smooth muscle relaxation in the airways.
Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.
Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma, chronic bronchitis, emphysema)
FDA-approved: Treatment of asthma and chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity, bradycardia in preterm infants
2.5 mg (0.5 m L of 0.5% solution) via nebulization three to four times daily, as needed.
For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.
Terminal elimination half-life is 3–4 hours; prolonged in hepatic impairment (up to 8 hours).
Terminal elimination half-life 12 hours; clinical context: q12h dosing achieves steady-state in 2-3 days
Primarily hepatic via catechol-O-methyltransferase (COMT); also undergoes sulfate conjugation.
Primarily hepatic via CYP1A2 and CYP3A4; also metabolized by xanthine oxidase and N-acetyltransferase. Metabolites excreted renally.
Primarily renal excretion as sulfate conjugates; unchanged drug accounts for <10% of excretion. Biliary/fecal excretion is minimal (<2%).
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites), 5% other
40–60% bound to albumin, with some binding to alpha-1-acid glycoprotein.
65% bound to albumin
Approximately 0.5 L/kg, indicating distribution into total body water and moderate tissue binding.
2.5 L/kg (extensive tissue distribution, suggests high lung penetration)
Inhalation: 10–20% (variable due to deposition and first-pass metabolism); oral: <1% due to extensive first-pass metabolism.
Oral: 40% (first-pass metabolism); Inhaled: 20% (lung deposition)
No dose adjustment required for renal impairment.
No dose adjustment required for renal impairment. Drug is primarily hepatically metabolized and renally excreted as inactive metabolites; however, significant accumulation is not expected in renal dysfunction.
No specific guidelines; use caution in severe hepatic impairment.
Child-Pugh Class A: No dose adjustment. Class B: Reduce dose to 50% of normal, monitor for adverse effects. Class C: Use with caution; reduce dose to 25-50% and monitor closely. Specific data for AEROLATE limited; adjust based on clinical response and tolerance.
0.01-0.03 m L/kg of 0.5% solution (maximum 0.5 m L) via nebulization every 4-6 hours as needed.
Children 4-11 years: 1-2 inhalations (90 mcg each) twice daily; maximum 2 inhalations twice daily. Children 12 years and older: Same as adult dosing. Administer via inhaler with spacer for optimal delivery. Weight-based dosing not typically used; fixed doses per age group.
Initiate at lowest effective dose; monitor for tachycardia and hypertension.
No specific dose adjustment required. Use lowest effective dose due to potential for increased systemic exposure from reduced clearance and higher risk of adverse effects (e.g., osteoporosis, hyperglycemia). Monitor for cardiac effects and adrenal suppression.
None
No FDA black box warning.
Paradoxical bronchospasm may occur with excessive use,Cardiovascular effects: tachycardia, hypertension, arrhythmias,Hypokalemia may occur with high doses,Caution in patients with hyperthyroidism, diabetes mellitus, or seizure disorders
Monitor serum theophylline levels due to narrow therapeutic index (10-20 mcg/m L).,Risk of toxicity at high levels: seizures, arrhythmias, death.,Use with caution in patients with hepatic impairment, heart failure, fever, or elderly.,Cigarette smoking and certain drugs (e.g., rifampin, phenytoin) induce metabolism; others (e.g., cimetidine, macrolides) inhibit metabolism.
Hypersensitivity to isoetharine or any component,Cardiac arrhythmias associated with tachycardia,Tachycardia or heart block caused by digitalis intoxication
Hypersensitivity to theophylline or any component.,Active peptic ulcer disease.,Uncontrolled seizure disorders.
No significant food interactions. Avoid excessive caffeine intake as it may increase beta-agonist side effects (tremor, tachycardia). No specific dietary restrictions.
Avoid excessive caffeine intake (coffee, tea, cola, chocolate) as it may potentiate CNS stimulation and toxicity. Food does not significantly affect absorption, but high-fat meals may delay absorption. Consistent dietary habits are recommended.
FDA Pregnancy Category C. In first trimester, limited data; animal studies show no teratogenicity at high doses. Second and third trimesters: no known fetal risks from inhaled bronchodilator use; systemic exposure minimal. However, uncontrolled asthma poses greater risk (maternal hypoxia, preterm birth).
AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theophylline crosses the placenta and can cause fetal tachycardia, jitteriness, and irritability; apneic episodes and respiratory failure reported in neonates exposed near term. Risk of preterm labor and low birth weight associated with maternal asthma exacerbation.
Excreted in breast milk in small amounts. M/P ratio not reported. Inhaled route minimizes systemic absorption; unlikely to affect nursing infant. Use with caution, weigh risks vs benefits.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.67. Peak milk levels occur 1-2 hours after maternal dosing. Estimated infant dose is about 1-10% of maternal weight-adjusted dose. Caution: irritability and jitteriness reported in breastfed infants. Avoid breastfeeding if maternal serum theophylline levels exceed 20 mcg/m L.
No dose adjustment typically required. Pregnancy may alter asthma severity; titrate dose to achieve symptom control. Inhaled beta-2 agonists generally safe; no significant pharmacokinetic changes reported.
Pregnancy may increase theophylline clearance (especially in second and third trimesters) due to increased renal perfusion and hepatic metabolism. Dose adjustments often required to maintain therapeutic levels. Initiate at standard dose and titrate based on serum levels and clinical response. Postpartum clearance decreases rapidly; doses should be reduced to pre-pregnancy levels within 2-4 weeks after delivery.
Bronkosol (isoetharine) is a beta-2 selective bronchodilator, but with less beta-2 selectivity than albuterol; monitor for tachycardia and tremor. It is administered via nebulization; ensure proper equipment and technique. Onset within 2-5 minutes, duration 1-3 hours. Not a first-line agent; use primarily for acute bronchospasm when albuterol is unavailable. Paradoxical bronchospasm can occur; discontinue if worsens.
AEROLATE (theophylline) has a narrow therapeutic index; monitor serum levels (target 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease or seizure disorders unless essential. Caution with hepatic impairment, heart failure, and in elderly due to reduced clearance. Drug interactions: cimetidine, fluoroquinolones, macrolides, and CYP1A2 inhibitors increase levels; smoking and rifampin decrease levels.
Use exactly as prescribed; do not increase dose or frequency without consulting your doctor.,If you miss a dose, use it as soon as you remember, but skip if it's almost time for the next dose; do not double up.,Rinse your mouth with water after each use to prevent dryness and irritation.,Seek immediate medical help if symptoms worsen or you experience chest pain, fast heartbeat, or difficulty breathing after use.,Store at room temperature away from moisture and heat; keep nebulizer clean per instructions.
Take exactly as prescribed; do not change dose or frequency without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid consuming large amounts of caffeine (coffee, tea, cola, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, rapid heartbeat, or seizures.,Do not smoke or stop smoking without informing your doctor, as smoking affects the drug's metabolism.,Keep a list of all medications you take, including over-the-counter drugs and herbal supplements.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BRONKOSOL vs AEROLATE, answered by our medical review team.
BRONKOSOL is a Bronchodilator that works by Bronchodilator via beta-2 adrenergic receptor agonism, increasing intracellular c AMP, leading to smooth muscle relaxation in the airways.. AEROLATE is a Bronchodilator that works by Theophylline competitively inhibits phosphodiesterase, increasing c AMP levels, and acts as an adenosine receptor antagonist, leading to bronchodilation and reduced airway inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BRONKOSOL and AEROLATE depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BRONKOSOL is: 2.5 mg (0.5 m L of 0.5% solution) via nebulization three to four times daily, as needed.. The standard adult dose of AEROLATE is: For asthma and COPD: 1-2 inhalations (90 mcg each) via metered-dose inhaler, 2 puffs twice daily, maximum 4 puffs twice daily. For acute exacerbations: 4-8 puffs every 20 minutes for up to 4 hours, then every 1-4 hours as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BRONKOSOL and AEROLATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BRONKOSOL is classified as Category C. FDA Pregnancy Category C. In first trimester, limited data; animal studies show no teratogenicity at high doses. Second and third trimesters: no known fetal risks from inhaled bron. AEROLATE is classified as Category C. AEROLATE (theophylline) is classified as FDA Pregnancy Category C. First trimester: No well-controlled studies; potential risk cannot be excluded. Second and third trimesters: Theo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.